The company announced third quarter results on Thursday 11-9-17. The company benefited from the sale of CTP-656 to Vertex as a one-time revenue that produced results of $5.61 in earnings per share for the quarter. More notable were some other developments.
The next important catalyst to watch for is the PGR decision to be made in January of 2018, the DMC decision for 4mg of CTP-543 around February, and two new indications will be announced early 2018. Thank you for reading.
- Cash runway of $207 million expected to last into 2021
- Expanded pipeline with a new neurological indication forthcoming
- A second indication for CTP-543 will be announced in 1st quarter of 2018
- Phase 2A for Alopecia Areata 4mg dose completed enrollment
- Data Monitoring Committee to give safety opinion around February 2018 4mg dose
- PGR (Post Grant Review) of Incyte's deuterated Ruxolitinib to be decided in January 2018
The next important catalyst to watch for is the PGR decision to be made in January of 2018, the DMC decision for 4mg of CTP-543 around February, and two new indications will be announced early 2018. Thank you for reading.
No comments:
Post a Comment